Hydralazine HClCAS# 304-20-1 |
- DAPT (GSI-IX)
Catalog No.:BCC3618
CAS No.:208255-80-5
- Semagacestat (LY450139)
Catalog No.:BCC3610
CAS No.:425386-60-3
- AR-A014418
Catalog No.:BCC1366
CAS No.:487021-52-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 304-20-1 | SDF | Download SDF |
| PubChem ID | 9351 | Appearance | Powder |
| Formula | C8H9ClN4 | M.Wt | 196.64 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | H2O : 25 mg/mL (127.14 mM; Need ultrasonic) | ||
| Chemical Name | phthalazin-1-ylhydrazine;hydrochloride | ||
| SMILES | [H+].[Cl-].NNc1nncc2ccccc12 | ||
| Standard InChIKey | ZUXNZUWOTSUBMN-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C8H8N4.ClH/c9-11-8-7-4-2-1-3-6(7)5-10-12-8;/h1-5H,9H2,(H,11,12);1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Hydralazine HCl Dilution Calculator
Hydralazine HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5.0854 mL | 25.4272 mL | 50.8544 mL | 101.7087 mL | 127.1359 mL |
| 5 mM | 1.0171 mL | 5.0854 mL | 10.1709 mL | 20.3417 mL | 25.4272 mL |
| 10 mM | 0.5085 mL | 2.5427 mL | 5.0854 mL | 10.1709 mL | 12.7136 mL |
| 50 mM | 0.1017 mL | 0.5085 mL | 1.0171 mL | 2.0342 mL | 2.5427 mL |
| 100 mM | 0.0509 mL | 0.2543 mL | 0.5085 mL | 1.0171 mL | 1.2714 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Hydralazine HCl
- Reutericyclin
Catalog No.:BCN1855
CAS No.:303957-69-9
- U 18666A
Catalog No.:BCC7136
CAS No.:3039-71-2
- L-779,450
Catalog No.:BCC7593
CAS No.:303727-31-3
- Dalbergioidin
Catalog No.:BCN4801
CAS No.:30368-42-4
- Centrolobol
Catalog No.:BCN5216
CAS No.:30359-01-4
- TAK-715
Catalog No.:BCC3968
CAS No.:303162-79-0
- Picrasin B acetate
Catalog No.:BCN5215
CAS No.:30315-04-9
- Pandamarilactonine B
Catalog No.:BCN5214
CAS No.:303008-81-3
- Pandamarilactonine A
Catalog No.:BCN5213
CAS No.:303008-80-2
- Coenzyme Q10
Catalog No.:BCN5954
CAS No.:303-98-0
- Ochratoxin A
Catalog No.:BCC7008
CAS No.:303-47-9
- Gossypol
Catalog No.:BCN2702
CAS No.:303-45-7
- Harmaline
Catalog No.:BCN5218
CAS No.:304-21-2
- LU AA33810
Catalog No.:BCC7708
CAS No.:304008-29-5
- Corydalmine
Catalog No.:BCN5217
CAS No.:30413-84-4
- Pelirine
Catalog No.:BCN4077
CAS No.:30435-26-8
- Toxicarolisoflavone
Catalog No.:BCN6468
CAS No.:3044-60-8
- Dynasore
Catalog No.:BCC1088
CAS No.:304448-55-3
- AVE 0991
Catalog No.:BCC4032
CAS No.:304462-19-9
- Cyclomusalenone
Catalog No.:BCN4654
CAS No.:30452-60-9
- Theaflavin-3-gallate
Catalog No.:BCN2316
CAS No.:30462-34-1
- Theaflavin 3,3'-di-O-gallate
Catalog No.:BCN5920
CAS No.:30462-35-2
- Xerophilusin G
Catalog No.:BCN5219
CAS No.:304642-94-2
- S 24795
Catalog No.:BCC7700
CAS No.:304679-75-2
Relaxing effect of CEDO 8956 and hydralazine HCl in cultured smooth muscle cells versus pericytes: a preliminary study.[Pubmed:12022017]
Klin Monbl Augenheilkd. 2002 Apr;219(4):277-80.
BACKGROUND: It hs been reported that some glaucoma patients have deficient endothelial nitric oxide production. The effect of the presupposed nitrovasodilators CEDO 8956 and hydralazine hydrochloride (HCl) on bovine retinal microcirculation pericytes and ophthalmic artery smooth muscle cells are investigated. METHODS: Cells were cultured on silicone membranes and their contractile tone observed by phase contrast inverted microscopy before and after exposure by fluid exchange to different drugs at various concentrations. Experiments were conducted with pericytes in the absence (control) or in the presence (10 nM - 0.1 mM) of CEDO 8956, Hydralazine HCl, or sodium nitroprusside (SNP). Experiments were conducted with smooth muscle cells in the absence (control) or in the presence (0.1 mM) of CEDO 8956, or Hydralazine HCl. RESULTS: In comparison to control (- 0.56 +/- 10 %), pericytes were significantly relaxed by SNP (100 +/- 0 %, p < 0.001), but not by CEDO 8956 (9.2 +/- 15.4 %) or Hydralazine HCl (20.6 +/- 4.4 %). In comparison to control (1.64 +/- 5.3 %), smooth muscle cells were significantly relaxed by CEDO 8956 (46.2 +/- 12.4 %, p < 0.05) and Hydralazine HCl (54.9 +/- 9.1 %, p < 0.001). CONCLUSIONS: These results suggest a possible heterogeneity between cultured bovine microcirculation pericytes and ophthalmic artery vascular smooth muscle cells in the relaxing response to CEDO 8956 and Hydralazine HCl. Apparently, these two drugs might not be first choice candidates in order to attempt to try to selectively improve circulation in the retina or the optic nerve head capillary network.
Cardiovascular effects of hydralazine HCl administration in horses.[Pubmed:3395006]
Am J Vet Res. 1988 May;49(5):618-21.
Six standing awake adult horses were instrumented for measurement of mean arterial, central venous, and pulmonary arterial blood pressures (mm of Hg), thermodilution cardiac output (ml/kg/min), and pulmonary arterial blood temperature (C). Total peripheral resistance was calculated from these values. Base-line data were accumulated, and a single dose of Hydralazine HCl (0.5 mg/kg) was administered IV. Horses were monitored for 420 minutes after hydralazine administration. Mean arterial and central venous blood pressures did not change from the base-line values. Cardiac output and heart rate were increased above base-line values for 260 minutes. Total peripheral resistance was decreased for 240 minutes. Pulmonary arterial blood temperature was decreased for 60 minutes after drug administration. Mean pulmonary arterial pressure relative to the base-line mean was intermittently decreased during the study. Intravenously administered Hydralazine HCl appears to be an effective vasodilator, with moderate duration of action in horses.
